Compare $FTH vs $SGMT | Chartloom

Compare

$FTH vs $SGMT

Faeth Therapeutics, Inc · Sagimet Biosciences Inc

FTH

Faeth Therapeutics, Inc

SGMT

Sagimet Biosciences Inc

Compare $FTH vs $SGMT

Comparing Faeth Therapeutics, Inc and Sagimet Biosciences Inc

FTHFaeth Therapeutics, Inc

SGMTSagimet Biosciences Inc

FTHFaeth Therapeutics, Inc

Market cap

$671M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

79.1%

52W performance

79.1%

FCF yield

-5.0%

SGMTSagimet Biosciences Inc

Market cap

$551M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

194.48x

Rev growth (TTM)

—

YTD performance

49.1%

52W performance

22.2%

FCF yield

-7.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FTH

SGMT

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

SGMT

Sagimet Biosciences Inc

Market Cap

FTH$671M

SGMT$551M

Enterprise Value

FTH$644M

SGMT$386M

Price

FTH$26.03

SGMT$8.93

P/E Ratio

FTHN/A

SGMTN/A

P/S Ratio

FTH0.00x

SGMT0.00x

EV/Sales

FTH0.00x

SGMT0.00x

EV/EBITDA

FTH0.00x

SGMT0.00x

P/B Ratio

FTH4.08x

SGMT2.20x

P/FCF Ratio

FTHN/A

SGMTN/A

EV/FCF

FTH-19.02x

SGMT-9.24x

PEG Ratio

FTHN/A

SGMTN/A

Forward P/E (NTM)

FTHN/A

SGMTN/A

Forward P/S (NTM)

FTHN/A

SGMT194.48x

Revenue (TTM)

FTH$0

SGMT$0

Revenue Growth (YoY)

FTHN/A

SGMTN/A

Forward Rev Growth

FTH77.6%

SGMT89.0%

Gross Margin (TTM)

FTH0.0%

SGMT0.0%

Operating Margin (TTM)

FTH0.0%

SGMT0.0%

EBITDA Margin (TTM)

FTH0.0%

SGMT0.0%

Net Margin (TTM)

FTH0.0%

SGMT0.0%

FCF Margin (TTM)

FTHN/A

SGMTN/A

Net Income (TTM)

FTH$-196M

SGMT$-47M

FCF (TTM)

FTH$-34M

SGMT$-42M

EPS (TTM)

FTH-$34.65

SGMT-$0.89

ROE (TTM)

FTH-18959.0%

SGMT-3196.0%

ROA (TTM)

FTH-17568.0%

SGMT-3057.0%

ROIC (TTM)

FTH-18946.0%

SGMT-3196.0%

Cash

FTH$27M

SGMT$166M

Debt

FTH$0

SGMT$0

Net Cash/Debt

FTH$27M

SGMT$166M

Current Ratio (TTM)

FTH19.69x

SGMT45.02x

Quick Ratio (TTM)

FTH19.55x

SGMT44.43x

Debt/Equity (TTM)

FTH0.00x

SGMT0.00x

Debt/Assets (TTM)

FTH0.0%

SGMT0.0%

Interest Coverage (TTM)

FTHN/A

SGMTN/A

Net Debt/EBITDA (TTM)

FTH0.00x

SGMT0.00x

Beta

FTH2.05

SGMT3.54

52W Performance

FTH79.1%

SGMT22.2%

YTD Performance

FTH79.1%

SGMT49.1%

% from 52W High

FTH-38.2%

SGMT-22.0%

% from 52W Low

FTH93.8%

SGMT98.4%

Asset Turnover (TTM)

FTH0.00x

SGMT0.00x

FCF Yield (TTM)

FTH-5.0%

SGMT-7.6%

Earnings Yield (TTM)

FTH-29.1%

SGMT-8.5%

Dividend Yield (TTM)

FTHN/A

SGMTN/A

Rule of 40

FTH0.0

SGMT0.0

EV/GP/RG

FTHN/A

SGMTN/A

Ticker research

View FTH research View SGMT research

Metric	FTH Faeth Therapeutics, Inc	SGMT Sagimet Biosciences Inc
Market & Valuation
Market Cap	$671M	$551M
Enterprise Value	$644M	$386M
Price	$26.03	$8.93
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.08x	2.20x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.02x	-9.24x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	194.48x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	77.6%	89.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-196M	$-47M
FCF (TTM)	$-34M	$-42M
EPS (TTM)	-$34.65	-$0.89
ROE (TTM)	-18959.0%	-3196.0%
ROA (TTM)	-17568.0%	-3057.0%
ROIC (TTM)	-18946.0%	-3196.0%
Financial Health
Cash	$27M	$166M
Debt	$0	$0
Net Cash/Debt	$27M	$166M
Current Ratio (TTM)	19.69x	45.02x
Quick Ratio (TTM)	19.55x	44.43x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	3.54
52W Performance	79.1%	22.2%
YTD Performance	79.1%	49.1%
% from 52W High	-38.2%	-22.0%
% from 52W Low	93.8%	98.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-5.0%	-7.6%
Earnings Yield (TTM)	-29.1%	-8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FTH research	View SGMT research

Valuation

P/S Ratio

FTH

0.00x

SGMT

0.00x

EV/FCF

FTH

-19.02x

SGMT

-9.24x

Growth & revenue

Forward Revenue Growth

SGMT

89.0%

FTH

77.6%

Profitability & performance

Gross Margin

FTH

0.0%

SGMT

0.0%

ROE

SGMT

-3196.0%

FTH

-18959.0%

FCF Yield %

FTH

-5.0%

SGMT

-7.6%

52-Week Performance

FTH

79.1%

SGMT

22.2%

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

SGMT

Sagimet Biosciences Inc

Market Cap

FTH$671M

SGMT$551M

Enterprise Value

FTH$644M

SGMT$386M

Price

FTH$26.03

SGMT$8.93

P/E Ratio

FTHN/A

SGMTN/A

P/S Ratio

FTH0.00x

SGMT0.00x

EV/Sales

FTH0.00x

SGMT0.00x

EV/EBITDA

FTH0.00x

SGMT0.00x

P/B Ratio

FTH4.08x

SGMT2.20x

P/FCF Ratio

FTHN/A

SGMTN/A

EV/FCF

FTH-19.02x

SGMT-9.24x

PEG Ratio

FTHN/A

SGMTN/A

Forward P/E (NTM)

FTHN/A

SGMTN/A

Forward P/S (NTM)

FTHN/A

SGMT194.48x

Revenue (TTM)

FTH$0

SGMT$0

Revenue Growth (YoY)

FTHN/A

SGMTN/A

Forward Rev Growth

FTH77.6%

SGMT89.0%

Gross Margin (TTM)

FTH0.0%

SGMT0.0%

Operating Margin (TTM)

FTH0.0%

SGMT0.0%

EBITDA Margin (TTM)

FTH0.0%

SGMT0.0%

Net Margin (TTM)

FTH0.0%

SGMT0.0%

FCF Margin (TTM)

FTHN/A

SGMTN/A

Net Income (TTM)

FTH$-196M

SGMT$-47M

FCF (TTM)

FTH$-34M

SGMT$-42M

EPS (TTM)

FTH-$34.65

SGMT-$0.89

ROE (TTM)

FTH-18959.0%

SGMT-3196.0%

ROA (TTM)

FTH-17568.0%

SGMT-3057.0%

ROIC (TTM)

FTH-18946.0%

SGMT-3196.0%

Cash

FTH$27M

SGMT$166M

Debt

FTH$0

SGMT$0

Net Cash/Debt

FTH$27M

SGMT$166M

Current Ratio (TTM)

FTH19.69x

SGMT45.02x

Quick Ratio (TTM)

FTH19.55x

SGMT44.43x

Debt/Equity (TTM)

FTH0.00x

SGMT0.00x

Debt/Assets (TTM)

FTH0.0%

SGMT0.0%

Interest Coverage (TTM)

FTHN/A

SGMTN/A

Net Debt/EBITDA (TTM)

FTH0.00x

SGMT0.00x

Beta

FTH2.05

SGMT3.54

52W Performance

FTH79.1%

SGMT22.2%

YTD Performance

FTH79.1%

SGMT49.1%

% from 52W High

FTH-38.2%

SGMT-22.0%

% from 52W Low

FTH93.8%

SGMT98.4%

Asset Turnover (TTM)

FTH0.00x

SGMT0.00x

FCF Yield (TTM)

FTH-5.0%

SGMT-7.6%

Earnings Yield (TTM)

FTH-29.1%

SGMT-8.5%

Dividend Yield (TTM)

FTHN/A

SGMTN/A

Rule of 40

FTH0.0

SGMT0.0

EV/GP/RG

FTHN/A

SGMTN/A

Ticker research

View FTH research View SGMT research

Metric	FTH Faeth Therapeutics, Inc	SGMT Sagimet Biosciences Inc
Market & Valuation
Market Cap	$671M	$551M
Enterprise Value	$644M	$386M
Price	$26.03	$8.93
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.08x	2.20x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.02x	-9.24x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	194.48x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	77.6%	89.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-196M	$-47M
FCF (TTM)	$-34M	$-42M
EPS (TTM)	-$34.65	-$0.89
ROE (TTM)	-18959.0%	-3196.0%
ROA (TTM)	-17568.0%	-3057.0%
ROIC (TTM)	-18946.0%	-3196.0%
Financial Health
Cash	$27M	$166M
Debt	$0	$0
Net Cash/Debt	$27M	$166M
Current Ratio (TTM)	19.69x	45.02x
Quick Ratio (TTM)	19.55x	44.43x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	3.54
52W Performance	79.1%	22.2%
YTD Performance	79.1%	49.1%
% from 52W High	-38.2%	-22.0%
% from 52W Low	93.8%	98.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-5.0%	-7.6%
Earnings Yield (TTM)	-29.1%	-8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FTH research	View SGMT research